March 1, 2000HeartOpen Access

Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients

View Full Paper

Ask AI

Bookmark

Why the study?

Does percutaneous transluminal septal myocardial ablation improve symptoms and reduce left ventricular outflow gradient in patients with drug-resistant hypertrophic obstructive cardiomyopathy?

Population

25 patients with drug treatment resistant New York Heart Association class 2.8 symptoms attributed to a high…

Design

Case_series

Follow-up

30 (4) months, range 24-36 months

Authors

LFLothar FaberHeart Failure & Transplant

Discussion

Member takes

Implication

Sustained LVOTG reduction with PTSMA may support durability in drug-resistant HOCM; leaves open need for randomized confirmation.

Structured PICO

Does percutaneous transluminal septal myocardial ablation improve symptoms and reduce left ventricular outflow gradient in patients with drug-resistant hypertrophic obstructive cardiomyopathy?

Population

25 patients (13 women, 12 men, mean age 54.7 years) with drug treatment resistant New York Heart Association (NYHA) class 2.8 symptoms attributed to a high left ventricular outflow gradient (LVOTG) and a coronary artery anatomy suitable for intervention.

Intervention

Percutaneous transluminal septal myocardial ablation (PTSMA) by injection of 4.1 (2.6) ml of alcohol (96%) into 1.4 (0.6) septal perforator arteries.

Outcome

In-hospital enzyme rise, frequency of atrioventricular conduction lesions requiring permanent DDD pacing, in-hospital mortality, and long-term symptoms, echocardiographic measurements of left atrial and left ventricular dimensions and function, and LVOTG.

PTSMA is an effective non-surgical technique that provides sustained reduction in left ventricular outflow gradient and symptomatic improvement in patients with drug-resistant hypertrophic obstructive cardiomyopathy.

Limitations

Small sample size
Need for prospective observations

Cite This Study

Lothar Faber (2000) studied this question.

synapsesocial.com/papers/6a8077a4377c56ad3031edcd https://doi.org/10.1136/heart.83.3.326

Topics

Echocardiography Hypertrophic cardiomyopathy

View Full Paper

Ask AI

Bookmark

Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients

Discussion

Member takes

Implication

Structured PICO

Limitations

Cite This Study

Topics

Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients

Discussion

Member takes

Implication

Structured PICO

Limitations

Cite This Study

Also Consider

Topics

Also Consider